Rezūm water-vapor therapy,
does it really help with Improvement of moderate-to-severe lower urinary tract symptoms caused by benign prostatic hyperplasia?
research showsThe grade is C. In a sham-controlled trial, 197 men were randomized 136 versus 61; three-month IPSS fell by 11.2±7.6 versus 4.3±6.9 points (P<0.0001). The 6.9-point between-group change corresponds to a large standardized effect of about 0.93. The 2016 pivotal paper's own Funding text could not be checked, but a follow-up report from the same trial states NxThera sponsorship; efficacy included 195 men, giving C with 50 points.
ads claimThe device genuinely creates water vapor to ablate tissue, and the trial genuinely found better three-month symptoms than sham. Those facts do not establish superiority over medication or surgery, nor prevention of retreatment across all prostate sizes.
Useful facts when choosing a product
- The device uses radiofrequency-generated water vapor to create thermal lesions in prostatic transition-zone tissue.
- The trial randomized 197 men, 136 versus 61, and analyzed IPSS efficacy in 195, 134 versus 61.
- The registered three-month IPSS primary outcome matched the paper, and controls underwent rigid cystoscopy with simulated sounds.
Chamgap Semantic Classification Code
Candidate index · review held
UNK.rezum-transurethral-convective-water-vapor-thermal-therapy.UNK.moderate-to-severe-lower-urinary-tract-symptoms-caused-by-benign-prostatic-hyperplasia.reduce.shamUnknown > Rezūm transurethral convective water-vapor thermal therapy > Unknown > moderate-to-severe lower urinary tract symptoms caused by benign prostatic hyperplasia > Reduction claim > Sham procedure or device
An automated migration candidate, not an issued permanent code; exact claim scope remains under review. This machine-generated migration candidate helps retrieval but is not a permanent assignment. The original verdict ID and URL remain authoritative.
What the research actually shows
McVary KT et al. randomized 197 men aged at least 50 with IPSS at least 13 and prostate volume 30–80 mL in a 2:1 ratio. Controls received rigid cystoscopy with simulated treatment sounds, and three-month IPSS change was the primary endpoint. Efficacy included 195 men, 134 versus 61, while safety included all 197. The 2016 pivotal paper's own Funding text was not accessible. The four-year follow-up from the same trial (PMID 30677455) states, ‘The clinical study was sponsored by NxThera Inc.’ It is follow-up of the same trial and was not counted as replication. Existing BPH verdicts address drugs or transurethral resection; this verdict addresses a transurethral water-vapor ablation device.
Why this is classified as C (50)
A large symptom effect was demonstrated against sham, but manufacturer sponsorship documented in a follow-up report from the same trial, one confirmatory trial, and fewer than 200 randomized participants give C with 50 points.
Counterpoint. C does not mean no effect. It reflects a large direct effect supported at a limited and nonindependent evidence level.
Rejudgment record. Cross-check applied — We cross-checked analysis denominators, primary outcome, sham procedure, and registry against the pivotal paper; sponsorship was verified in the four-year follow-up from the same trial.
| Endpoint | P | Symptom or function itself is the target - including patient reports and performance tests |
| Replication | R1 | Single confirmatory trial |
| Independence | I0 | Evidence comes only from manufacturer studies |
| Effect size | E+ | Meets the clinically important threshold |
Stored derived and displayed grades match; this is not a current recalculation or validity check (C).
Sub-claim grades by effect
This ingredient is marketed for several effects. A single overall grade blends strong and weak claims together, so each effect is graded separately here. The overall grade reflects the strongest disconfirming or core claim.
| Effect (sub-claim) | Grade | Basis |
|---|---|---|
| Improved urinary symptoms at three months | C | IPSS reduction was 6.9 points greater than with sham. |
| Superiority to medication or transurethral resection | ? | The pivotal trial used sham control and did not make this direct comparison. |
Cross-check — AI research and Codex final gate
Evidence Table
| Study | Design | Sample | Funding | Endpoint | Result | Weight |
|---|---|---|---|---|---|---|
| McVary KT, Gange SN, Gittelman MC, Goldberg KA et al., 2016 | Multicenter 2:1 randomized participant-masked sham-controlled trial | 197 randomized, 136 versus 61; 195 in IPSS efficacy analysis, 134 versus 61 | The 2016 paper's own Funding text was not verified; the four-year follow-up from the same trial states NxThera Inc. sponsorship | Change from baseline in IPSS at three months | −11.2±7.6 versus −4.3±6.9 points, P<0.0001; between-group change difference 6.9 points, standardized difference about 0.93 | Pivotal sham-controlled symptom trial |
| McVary KT, Rogers T, Roehrborn CG, 2019 four-year follow-up | Long-term follow-up report from the same NCT01912339 randomized trial | Same pivotal-trial cohort | ‘The clinical study was sponsored by NxThera Inc.’ | Four-year symptom durability and retreatment | Follow-up used to verify sponsorship; not counted as separate replication | Follow-up of the same trial |
Receipt — 2 References
Of 2 cited sources, 1 had limited original-page access (blocked or summary-only) and were verified via index/summary, marked partial; the rest were verified at the original page. As of 2026-08-14.
Final verification and publication gate: Codex · Evidence date: 2026-08-14 · Corrections: none
Cite this verdict
[Chamgap] Rezūm water-vapor therapy x improvement of BPH urinary symptoms — Evidence Grade C·50. 2 cited sources checked. Source: https://chamgap.com/en/verdicts/mens/rezum-water-vapor-bph-luts-improvement/ · CC BY 4.0CC BY 4.0 — free to use with attribution; do not distort grades, numbers, or verdict meaning.
What this document does and does not do
Chamgap is an information source. It reports what research has and has not confirmed; it does not tell readers what to take or buy. That decision belongs to readers and, when needed, medical or legal professionals. This verdict reflects literature available up to the search date and may change as new research appears. Nothing here is medical advice.